We are live on
!
Find out more
FLSM
Frazier Life Sciences Management Portfolio holdings
AUM
$4.59B
1-Year Est. Return
237.58%
This Fund
S&P 500
This Quarter
Est. Return
+24.25%
1 Year Est. Return
+237.58%
3 Year Est. Return
+865.83%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$4.59B
AUM Growth
+$706M
(+18%)
Cap. Flow
-$31.5M
Cap. Flow
% of AUM
-0.69%
Top 10 Holdings %
Top 10 Hldgs %
73.61%
Holding
44
New
6
Increased
8
Reduced
2
Closed
3
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
PBLS
Parabilis Medicines Inc
PBLS
|
+$53.1M |
| 2 |
Allogene Therapeutics
ALLO
|
+$41M |
| 3 |
NewAmsterdam Pharma
NAMS
|
+$37.7M |
| 4 |
Achieve Life Sciences
ACHV
|
+$36.3M |
| 5 |
KLRA
Kailera Therapeutics
KLRA
|
+$24.2M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
BridgeBio Pharma
BBIO
|
+$133M |
| 2 |
KALV
KalVista Pharmaceuticals
KALV
|
+$99.9M |
| 3 |
Revolution Medicines
RVMD
|
+$65.7M |
| 4 |
Agios Pharmaceuticals
AGIO
|
+$42.5M |
| 5 |
Trevi Therapeutics
TRVI
|
+$1.45K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 99.77% |
| 2 | Miscellaneous | 0.23% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Mirum Pharmaceuticals
MIRM
$5.94B
| $899M | 19.58% |
7,679,684
| – | – |
|
|
2
NewAmsterdam Pharma
NAMS
$3.1B
| $613M | 13.35% |
18,088,902
+1,145,128
| +7% | +$37.7M |
|
3
Erasca
ERAS
$6.31B
| $458M | 9.96% |
24,975,188
+300,000
| +1% | +$4.29M |
|
|
MBX
4
MBX Biosciences
MBX
$3.03B
| $367M | 8% |
6,652,013
| – | – |
|
5
Arcutis Biotherapeutics
ARQT
$2.99B
| $259M | 5.64% |
9,874,511
| – | – |
|
|
6
Trevi Therapeutics
TRVI
$2.39B
| $185M | 4.04% |
9,939,447
-100
| -0% | -$1.45K |
|
7
Krystal Biotech
KRYS
$10.4B
| $179M | 3.9% |
481,307
| – | – |
|
|
MAZE
8
Maze Therapeutics
MAZE
$1.52B
| $150M | 3.27% |
5,032,915
+465,641
| +10% | +$12.2M |
|
9
Phathom Pharmaceuticals
PHAT
$743M
| $135M | 2.95% |
12,466,489
| – | – |
|
|
PVLA
10
Palvella Therapeutics
PVLA
$2.16B
| $135M | 2.94% |
882,400
| – | – |
|
|
11
BridgeBio Pharma
BBIO
$15B
| $115M | 2.51% |
1,548,139
-1,900,000
| -55% | -$133M |
|
12
Disc Medicine
IRON
$3.07B
| $99.1M | 2.16% |
1,354,852
| – | – |
|
13
Cytokinetics
CYTK
$10B
| $98.8M | 2.15% |
1,159,879
| – | – |
|
14
Dyne Therapeutics
DYN
$4.68B
| $70M | 1.53% |
3,153,082
| – | – |
|
15
Ascendis Pharma A/S
ASND
$16.3B
| $60.1M | 1.31% |
225,155
+91,822
| +69% | +$21.4M |
|
16
Savara
SVRA
$1.08B
| $59.9M | 1.3% |
9,720,852
| – | – |
|
|
PBLS
17
Parabilis Medicines Inc
PBLS
$4.83B
| $52.6M | 1.14% |
+1,920,805
| New | +$53.1M |
|
18
Aura Biosciences
AURA
$767M
| $50.4M | 1.1% |
7,100,000
+2,000,000
| +39% | +$14.3M |
|
|
19
Achieve Life Sciences
ACHV
$834M
| $49.7M | 1.08% |
+7,614,836
| New | +$36.3M |
|
20
Vor Biopharma
VOR
$1.34B
| $46.8M | 1.02% |
2,543,939
| – | – |
|
|
21
Allogene Therapeutics
ALLO
$698M
| $46.7M | 1.02% |
22,446,668
+18,650,000
| +491% | +$41M |
|
22
Tarsus Pharmaceuticals
TARS
$3.15B
| $45.9M | 1% |
728,644
| – | – |
|
23
BioCryst Pharmaceuticals
BCRX
$2.51B
| $40.1M | 0.87% |
4,009,240
| – | – |
|
24
Alkermes
ALKS
$7.95B
| $36.7M | 0.8% |
700,647
| – | – |
|
25
Acadia Pharmaceuticals
ACAD
$5.02B
| $36.4M | 0.79% |
1,438,198
| – | – |
|
Similar funds
AF
BWA
CCA
AT
SLG
TYCC
LP
CSP
Frazier Life Sciences Management's Q2 2026 Portfolio in Review
As of Q2 2026, Frazier Life Sciences Management held 44 positions worth $4.59B, up 18% from $3.89B the previous quarter. Its ten largest holdings account for 74% of the portfolio.
Frazier Life Sciences Management's Q2 2026 filing shows 6 new, 8 increased, 2 reduced and 3 closed positions. Its largest new stake was Parabilis Medicines Inc: 1,920,805 shares worth $52.6M. The largest sale was BridgeBio Pharma, an estimated $133M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Miscellaneous.
- Frazier Life Sciences Management's largest Q2 2026 buy was Parabilis Medicines Inc: 1,920,805 shares worth $52.6M.
- Frazier Life Sciences Management added most to Allogene Therapeutics in Q2 2026, an estimated $41M increase.
- Frazier Life Sciences Management's biggest Q2 2026 reduction was BridgeBio Pharma, cutting an estimated $133M.
- Frazier Life Sciences Management fully exited KalVista Pharmaceuticals in Q2 2026, selling an estimated $99.9M.
- Frazier Life Sciences Management's ten largest holdings make up 74% of its $4.59B portfolio in Q2 2026.
- Frazier Life Sciences Management opened 6 new positions and closed 3 in Q2 2026.
- Frazier Life Sciences Management's portfolio value rose 18% quarter-over-quarter to $4.59B.
Based on Frazier Life Sciences Management's 13F filing for Q2 2026, filed 14 Aug 2026.